Despite the success of antiretroviral therapy (ART), there is currently no HIV cure and
treatment is life long. HIV persists during ART due to long-lived and proliferating latently …

Human immunodeficiency virus type 1 (HIV-1) infection persists despite years of
antiretroviral therapy (ART). To remove the stigma and burden of chronic infection …

Reversal of HIV-1 latency by small molecules is a potential cure strategy. This approach will
likely require effective drug combinations to achieve high levels of latency reversal. Using …

The early effectiveness of combinatorial antiretroviral therapy (cART) in the treatment of HIV
infection has been compromised to some extent by rapid development of multidrug-resistant …

Effective antiretroviral therapy (ART) blunts viraemia, which enables HIV-1-infected
individuals to control infection and live long, productive lives. However, HIV-1 infection …

Long noncoding RNAs (lncRNAs) may either repress or activate HIV-1 replication and
latency; however, specific mechanisms for their action are not always clear. In HIV-1 infected …

Reversing HIV-1 latency promotes killing of infected cells and is essential for cure strategies;
however, no single latency reversing agent (LRA) or LRA combination have been shown to …

Unbiased shRNA library screens revealed that the estrogen receptor-1 (ESR-1) is a key
factor regulating HIV-1 latency. In both Jurkat T cells and a Th17 primary cell model for HIV-1 …

Although potent combination antiretroviral therapy can effectively block viral replication in
the host, human immunodeficiency virus (HIV) persists due to the existence of latent but …

Current antiretroviral therapy does not eliminate the integrated and transcriptionally silent
HIV-1 provirus in latently infected cells. Recently, a “shock and kill” strategy has been …